Related Experiment Videos
Organ transplantation in the vasculitides
Wilhelm H Schmitt1, Fokko J van der Woude
1Vth Medical Clinic (Nephrology, Endocrinology), University-Clinic Mannheim, Faculty of Clinical Medicine of The University of Heidelberg, Germany. wilhelm.schmitt@med5.ma.uni-heidelberg.de
Abstract:
Despite important therapeutic improvements, permanent organ failure may develop in primary systemic vasculitides and affect the heart, the lungs, and especially the kidneys. In systemic vasculitides associated with antineutrophil cytoplasmic antibodies (AASV), end-stage renal failure develops in 20% of cases. Renal transplantation became a beneficial option in these patients, with a graft and patient survival comparable to that in nondiabetic patients. This review summarizes the current knowledge on indications and contraindications for renal transplantation in AASV and discusses the impact of posttransplant immunosuppression on the course of the patients.
Insights
Systemic vasculitides can cause kidney failure, but renal transplantation offers a good option for patients with antineutrophil cytoplasmic antibody-associated vasculitis (AASV). Outcomes are comparable to those in nondiabetic patients, with careful consideration of transplant criteria and immunosuppression.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Primary systemic vasculitides can lead to permanent organ damage, particularly kidney failure.
- Antineutrophil cytoplasmic antibody-associated vasculitis (AASV) results in end-stage renal failure in 20% of affected individuals.
- Renal transplantation is an established and effective treatment for AASV patients with kidney failure.
Purpose of the Study:
- To review the indications and contraindications for renal transplantation in AASV patients.
- To discuss the influence of post-transplant immunosuppression on patient outcomes in AASV.
- To provide an overview of current knowledge regarding renal transplantation for AASV.
Main Methods:
- Literature review of studies on renal transplantation in AASV.
- Analysis of patient and graft survival rates.
- Discussion of immunosuppressive strategies post-transplantation.
Main Results:
- Renal transplantation in AASV patients demonstrates graft and patient survival rates comparable to those in nondiabetic recipients.
- Successful transplantation can significantly improve quality of life and long-term prognosis for AASV patients with end-stage renal disease.
- Careful selection of candidates and management of immunosuppression are crucial for optimal outcomes.
Conclusions:
- Renal transplantation is a viable and effective therapeutic option for AASV patients experiencing end-stage renal failure.
- Understanding specific indications, contraindications, and post-transplant management is essential for successful outcomes.
- Further research into immunosuppressive protocols may further enhance long-term graft survival and patient well-being.